Vascular endothelial growth factor (VEGF)
- Endocrinology & neuroendocrinology
- Genetic medicine
- Oncology & pharmacology
- Prostatic conditions
Note: Within each section, papers are in reverse chronological order.
Sun S, Wang YC, Guo K, Du J, Zhou HJ, Ren AJ. [Finasteride inhibits microvascular density and VEGF expression in the seminal vesicle of rats]. Zhonghua Nan Ke Xue. 2018 May. Chinese. PubMed
Finasteride can inhibit the expression of VEGF in the seminal vesicle tissue of the rat and hence suppress the angiogenesis of microvessels of the seminal vesicle.
Hatanaka T, Lulic Z, Mefo T, Booth C, Harrison E, Ong G. Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors – dutasteride and finasteride – in the presence of testosterone. Singapore Med J. 2021 Jun 22. DOI • PubMed
Lee CY, Su CH, Chiang CY, Wu CN, Kuan YH. Observation of the expression of vascular endothelial growth factor and the potential effect of promoting hair growth treated with Chinese herbal BeauTop. Evid Based Complement Alternat Med. 2021 Feb 17. DOI • PubMed • PMC full text
VEGF is considered the most important mediator for the process of angiogenesis involved in hair growth development.
Wang ZD, Feng Y, Sun L, et al. Anti-androgenetic alopecia effect of policosanol from Chinese wax by regulating abnormal hormone levels to suppress premature hair follicle entry into the regression phase. Biomed Pharmacother. 2021 Apr. DOI • PubMed
The cutaneous expression or activity of key mediators of hair growth, such as alkaline phosphatase (ALP), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF), was measured.
Growth factors affecting hair growth (i.e., IGF-1, HGF, FGF-7 and VEGF)
Lachgar S, Charvéron M, Aries MF, Gall Y, Bonafé JL. Follicules pilaires et “vascular endothelial growth factor” [Hair follicles and vascular endothelial growth factor]. Ann Dermatol Venereol. 1998 Apr. French. PubMed
Endocrinology & neuroendocrinology
Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS. Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol. 2011 Apr. DOI • PubMed • PMC full text
Zamora-Sánchez CJ, Hansberg-Pastor V, Salido-Guadarrama I, Rodríguez-Dorantes M, Camacho-Arroyo I. Allopregnanolone promotes proliferation and differential gene expression in human glioblastoma cells. Steroids. 2017 Mar. DOI • PubMed
Albasher G, Bin-Jumah M, Alfarraj S, et al. Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. Biosci Rep. 2020 Feb 28. DOI • PubMed • PMC full text
VGEF underexpressed; VKOR overexpressed (Fig. 5).
Oncology & pharmacology
Papers on prostate cancer are in the Prostatic Conditions section
P4 suppressed the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP-9, MMP-2), which are involved in tumor vascular development.
See Related research: Ophthalmology (VEGF is covered)
Peng Y, Peng C, Wu Y, Sun C, Li X. Chemical profiles of the active fraction from Prinsepia utilis Royle leaves and its anti-benign prostatic hyperplasia evaluation in animal models. BMC Complement Med Ther. 2021 Oct 29. DOI • PubMed
Abdel-Aziz AM, Gamal El-Tahawy NF, Salah Abdel Haleem MA, Mohammed MM, Ali AI, Ibrahim YF. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFβ and iNOS/COX-2. Eur J Pharmacol. 2020 Dec 15. DOI • PubMed
Angrimani DSR, Francischini MCP, Brito MM, Vannucchi CI. Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PLoS One. 2020 Jun 25. DOI • PubMed • PMC full text
Park HK, Kim SK, Lee SW, et al. A herbal formula, comprising Panax ginseng and bee-pollen, inhibits development of testosterone-induced benign prostatic hyperplasia in male Wistar rats. Saudi J Biol Sci. 2017 Nov. DOI • PubMed • PMC full text
Khwaja MA, Nawaz G, Muhammad S, Jamil MI, Faisal M, Akhter S. The effect of two weeks preoperative finasteride therapy in reducing prostate vascularity. J Coll Physicians Surg Pak. 2016 Mar. PubMed
Montico F, Kido LA, Hetzl AC, Cagnon VH. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate. 2015 Apr 1. DOI • PubMed
Kido LA, Hetzl AC, Cândido EM, Montico F, Lorencini RM, Cagnon VH. Antiangiogenic and finasteride therapies: responses of the prostate microenvironment in elderly mice. Life Sci. 2014 Jun 13. DOI • PubMed
Das K, Lorena PD, Ng LK, et al. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer. 2010 Aug 16. DOI • PubMed
Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol. 2006. DOI • PubMed
Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int. 2005 Dec. DOI • PubMed
Liu XD, Li H, Bu H, et al. [Effects of finasteride on capillary in the ventral prostate of rat]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Mar. Chinese. PubMed
Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003 Jan. DOI • PubMed